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ABSTRACT
Ovarian cancer is the fifth leading cause of cancer-related female deaths. Due 
to serious side effects, relapse and resistance to standard chemotherapy, better and 
more targeted approaches are required. Mutation of the TP53 gene accounts for 
50% of all human cancers. In the remaining malignancies, non-genotoxic activation 
of wild-type p53 by small molecule inhibition of the MDM2-p53 binding interaction 
is a promising therapeutic strategy. Proof of concept was established with the cis-
imidazoline Nutlin-3, leading to the development of RG7388 and other compounds 
currently in early phase clinical trials. This preclinical study evaluated the effect of 
Nutlin-3 and RG7388 as single agents and in combination with cisplatin in a panel 
of ovarian cancer cell lines. Median-drug-effect analysis showed Nutlin-3 or RG7388 
combination with cisplatin was additive to, or synergistic in a p53-dependent manner, 
resulting in increased p53 activation, cell cycle arrest and apoptosis, associated with 
increased p21WAF1 protein and/or caspase-3/7 activity compared to cisplatin alone. 
Although MDM2 inhibition activated the expression of p53-dependent DNA repair 
genes, the growth inhibitory and pro-apoptotic effects of p53 dominated the response. 
These data indicate that combination treatment with MDM2 inhibitors and cisplatin has 
synergistic potential for the treatment of ovarian cancer, dependent on cell genotype.
INTRODUCTION
Ovarian cancer is the most lethal of all gynecological 
malignancies and was reported to be responsible for 
approximately 152,000 deaths worldwide in 2012 [1]. 
Although patients with primary disease respond to platinum 
and taxane chemotherapy, relapse and resistance to treatment 
is prevalent, leading to lack of long-term benefit from 
treatment. For this reason, molecular alterations in tumors, 
particularly those involved in growth signaling pathways, 
cell cycle progression and apoptosis are being investigated to 
potentially exploit for targeted therapy (reviewed by [2, 3]).
The TP53 tumor suppressor gene is referred to as 
the most frequently altered gene in human cancers. It has 
been substantially established that p53 protects cells against 
environmental and intra-cellular stress stimuli by playing a 
central role in regulating cell cycle control, differentiation, 
proliferation, DNA repair and apoptosis (reviewed by [4]). 
TP53 mutation is the most frequent genetic abnormality in 
ovarian cancer, which accounts for 60% of ovarian cancers, 
with a particularly high prevalence in high grade serous 
tumors. In the remaining malignancies, p53 function is held 
in check through other mechanisms and reactivation of p53 
is a potential therapeutic strategy (reviewed by [5]).
MDM2 is the main negative regulator of p53, 
regulating p53 through ubiquitin dependent degradation. 
The imidazoline Nutlin-3, was the first non-genotoxic 
specific small-molecule antagonist of the MDM2-p53 
binding interaction to be developed [6] and has been 
used extensively as a probe compound in preclinical and 
mechanistic studies. RG7388 was subsequently developed 
as a second generation MDM2 inhibitor with superior 
potency, selectivity and oral bioavailability suitable for 
clinical development to inhibit the MDM2-p53 interaction 
and activate the p53 pathway [7, 8]. These compounds 
target a small hydrophobic pocket on MDM2, to which 
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p53 normally binds, leading to p53 stabilization and 
upregulation of p53 downstream transcriptional targets 
involved in cell cycle arrest and/or apoptosis, including 
genes encoding p21WAF1, BAX and BBC3 (PUMA) 
[9, 10]. Using MDM2-p53 antagonists as single-agent 
therapy has been suggested to be potentially limited due 
to acquisition of resistance through continuous exposure 
to MDM2 inhibitors followed by de novo mutations 
[11] and (reviewed by [12]). It is therefore logical to 
consider using MDM2 antagonists in combination with 
established therapeutic agents to improve treatment with 
the possibility of dose reduction and less normal tissue 
cytotoxicity and genotoxicity. In the context of ovarian 
cancer it is of interest to investigate the combination of 
cisplatin and MDM2 inhibitors, particularly as individually 
these agents have different dose limiting toxicities.
The aim of the present study was to test a panel of 
established ovarian cancer cell lines for their response to 
MDM2-p53 antagonists, Nutlin-3 and RG7388, alone and 
in combination with cisplatin and examine the mechanistic 
basis of these responses in relation to the genotype and 
induced gene expression of the cells.
RESULTS
Wild-type TP53 ovarian cancer cell lines are 
sensitive to Nutlin-3/RG7388
Growth inhibition by Nutlin-3/RG7388 was 
investigated using the sulforhodamine-B (SRB) assay 
for a panel of wild-type and mutant TP53 ovarian cancer 
cell lines derived from tumours of different histological 
subtypes [13-16] (Figure 1A and Table 1). The required 
concentration of each compound leading to 50% growth 
inhibition (GI
50
) showed that wild-type TP53 ovarian 
cancer cell lines were significantly more sensitive to 
Nutlin-3/RG7388 compared to mutant, which is consistent 
with their mechanism of action (p<0.0001 Mann-Whitney 
test). Also, RG7388 was more potent compared to Nutlin-3 
(p<0.0001 Mann-Whitney test). The GI
50
 values for 
wild-type TP53 cell lines for RG7388 and Nutlin-3 were 
in the nanomolar range ( 253.3 ± 73.1 (SEM) nM) and 
micromolar range (1.76 ± 0.51 (SEM) µM) respectively. 
In contrast, TP53 mutant cell lines had GI
50
 values greater 
than 10 μM (17.8 ± 2.9 (SEM) μM) for RG7388 and range 
21.2-˃30 μM for Nutlin-3 (Table 1 and Figure 1A).
Functional activation of the p53 pathway in wild-
type TP53 ovarian cancer cell lines in response to 
Nutlin-3/RG7388
The p53-dependent response to Nutlin-3/RG7388 
assessed by Western blotting (Figure 1B, 1C) showed 
that Nutlin-3/RG7388 induced stabilization of p53 
and upregulation of p21WAF1 and MDM2 protein levels 
four hours after the commencement of treatment in a 
concentration-dependent manner and confirmed functional 
activation of wild-type p53 by release from MDM2. 
However, as anticipated, it had no effect on p53-dependent 
gene expression in the TP53-mutant cell lines with the 
delivered dose range of Nutlin-3/RG7388. Interestingly 
this was despite a small increase in stabilization of mutant 
p53 in response to RG7388 at the doses of 0.1 and 0.5 µM 
with the CP70 and MLH1-corrected CP70+ cell lines. This 
result indicates that some forms of mutant p53 are still 
targeted for degradation by MDM2 even though they have 
lost their transcriptional function. Also, there is a frame-
shift deletion in the SKOV-3 cell line (Table 1) leading 
to an absence of detectable p53, p21WAF1 and MDM2 
expression (Figure 1B, 1C).
Nutlin-3/RG7388 synergizes with cisplatin for 
growth inhibition of wild-type TP53 ovarian 
cancer cell lines
The effect of Nutlin-3/RG7388 in combination 
with cisplatin was investigated for 3 wild-type TP53 
ovarian cancer cell lines using Median-effect analysis. 
The sensitivity of these TP53 wild-type cell lines to 
growth inhibition during 72 hours exposure to Nutlin-3, 
RG7388 and cisplatin was determined as single agents, 
and in combination at 5 equipotent concentrations 
between 0.25× and 4× their respective GI
50
 concentrations. 
The effect of combined treatment was cell type and 
compound dependent. Combination of Nutlin-3/RG7388 
with cisplatin at all concentrations led to greater growth 
inhibition compared to either agent alone for the 
A2780 cell line. Combination treatment of OAW42 and 
IGROV-1 cell lines also produced more growth arrest 
at concentrations equal to or lower than the individual 
1xGI
50
 dose (Figure 2A & 2B). To determine whether the 
observed differences in growth inhibition were additive 
or synergistic, the data were analyzed using median-effect 
analysis and Combination Index (CI) and Dose Reduction 
Index (DRI) values calculated.
CI values for each constant ratio combination and 
at effect levels of ED
50
, ED
75
 and ED
90
 were computed. 
Also, the average of CI values at ED
50
, ED
75
 and ED
90
 
was determined (Table 2 and Figure 2C). Across all cell 
lines, the effect of combination treatment of Nutlin-3/
RG7388 with cisplatin ranged from additive to synergistic 
based on the CI at ED
50
. Although the effect of combined 
treatment based on overall CI was synergism for 
A2780, it was antagonism for IGROV-1 and OAW42 
(Table 2 and Figure 2C). The data analysis showed there 
was a favourable dose reduction index (DRI), which 
demonstrates how many-fold the dose of each drug in a 
combination treatment may be reduced to achieve a given 
effect level compared with the doses of each drug alone 
(Table 3). Both Nutlin-3, and RG7388 had favorable DRI 
values for combined treatment with cisplatin, with most 
experimental values ranging from 1.1-fold to 6.9-fold dose 
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reduction. These DRI values have clinical implications, 
demonstrating a significant individual drug dose reduction 
may be achieved for a given combination therapeutic 
effect, compared with the dose of either drug alone as a 
single agent to obtain the same therapeutic effect.
The effect of combination treatment with 
Nutlin-3/RG7388 and cisplatin on p53 activation
Further analysis was performed to investigate the 
effect of combination treatment on the p53 molecular 
Figure 1: The sensitivity to MDM2 antagonists, Nutlin-3 and RG7388, in a panel of wild-type and mutant TP53 
ovarian cancer cell lines. A. Wild-type TP53 cell lines are significantly more sensitive to growth inhibition by Nutlin-3 (Mann Whitney 
test, p< 0.0001) and RG7388 (Mann Whitney test, p< 0.0001) treatment for 72 hours compared to mutant TP53 cell lines. Data shown are 
the average of at least three independent experiments and error bars represent SEM. Western blot analysis for B. Nutlin-3 and C. RG7388 
showed stabilization of p53 and upregulation of p53 transcriptional target gene protein levels, MDM2 and p21WAF1, four hours after the 
commencement of treatment in wild-type TP53 cell lines with the indicated doses (µM); however, they had no effect on downstream 
transcriptional targets of p53 in mutant TP53 ovarian cancer cell lines with the delivered dose range of MDM2 antagonists despite 
stabilization of the mutant p53 in the CP70 +and CP70+ cells. TP53 mutant cell lines are highlighted in bold font. D. DMSO treated control 
cells; CP70+, MLH1- Corrected CP70+.
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pathway using Western blotting. Wild-type TP53 cell 
lines were treated with Nutlin-3/RG7388 and cisplatin 
alone, and in combination at constant 1:1 ratios of 1x 
and 2x their respective GI
50
 concentration for 4 hours. 
Western analysis showed that treatment with Nutlin-3/
RG7388 and cisplatin as a single agent and in combination 
induced p53 stabilization and upregulation of p21WAF1 and 
MDM2, confirming functional activation of wild-type p53 
(Figure 3). Moreover, combination treatment in all cases 
led to greater levels of p53 stabilization, as well as p21WAF1 
and MDM2 upregulation compared to cisplatin on its own, 
and in most cases these were greater than those induced 
by Nutlin-3/RG7388 alone. Higher expression of p21WAF1 
for combined treatment was associated with a greater 
synergistic effect for growth inhibition. However, Nutlin-3 
and RG7388 led to little change in BAX expression 
compared to DMSO control, and their combination with 
cisplatin showed only a small increase in the expression 
of BAX compared to cisplatin on its own (Figure 3). 
Interestingly, cisplatin alone at a GI
50
 or 2x GI
50
 dose 
showed much less p53 pathway induction than Nutlin-3 
or RG7388 alone.
Nutlin-3/RG7388 in combination with cisplatin 
induces increased cell cycle distribution changes 
and/or apoptosis in wild-type TP53 ovarian 
cancer cell lines
Wild-type TP53 cell lines were treated with 
Nutlin-3/RG7388 and cisplatin, alone and in combination 
at constant 1:1 ratios of 1x and 2x (1/2 x & 1x for OAW42) 
their respective GI
50
 concentration for 24, 48 and 72 hours. 
They were then analyzed by flow cytometry for cell cycle 
phase distribution changes and evidence of apoptosis in 
response to treatment. The 48 and 72 hour treatment data 
is presented in the Supplementary Figures (S1–S4).
For the wild-type TP53 cell lines, Nutlin-3 only 
showed a modest increase in the proportion of cells in G0/
G1 phase in a dose and time dependent manner. Nutlin-3 
also increased the percentage of SubG1 events, a surrogate 
marker of apoptosis, in A2780 and IGROV-1 cell lines in 
a treatment time and dose-dependent manner (Figure 4A 
& 4B, Supplementary Figure S1B and Supplementary 
Figure S2B). For A2780 and IGROV-1 cells, combination 
treatment of Nutlin-3 with cisplatin led to a dose and time 
Table 1: GI50 concentrations of cisplatin, Nutlin-3 and RG7388 for the panel of ovarian cancer cell lines of varying 
TP53 status 
Cell line TP53 status Histotype 
& Reference
Cisplatin (µM) Nutlin-3 (µM) RG7388 (µM)
A2780 Wild-type Undifferentiated [12] 0.82 ± 0.17 1.23 ± 0.23 0.11 ± 0.01
IGROV-1 Wild-type Mixed, EC with CCC/
UD [14]
0.85 ± 0.04 2.8 ± 0.48 0.35 ± 0.04
OAW42 Wild-type
Serous 
Cystadenocarcinoma 
[13]
0.73 ± 0.02 1.3 ± 0.1 0.31 ± 0.04
CP70
Mutant 
(Heterozygous) 
c.514 G->T; 
p.Val172Phe
Undifferentiated [12] 5.8 ± 1.1 21.2 ± 2.5 11.7 ± 1.81
MLH1-Corrected 
CP70+
Mutant 
(Heterozygous) 
c.514 G->T; 
.Val172Phe
Undifferentiated [12] 2.4 ± 0.25 21.2 ± 1.22 14.5 ± 1.09
MDAH-2774
Mutant 
(Homozygous) 
c.818G->A; 
p.Arg273His
Endometrioid 
carcinoma [15]
1.11± 0.14 21.4 ± 0.9 20.7 ± 1.43
SKOV-3
Mutant 
(Homozygous) 
265delC; 
p.Pro89fsX33
Adenocarcinoma [13] 8.8 ± 0.49 ˃ 30 24.6 ± 1.54
Data represent the mean of at least 3 independent experiments ± SEM. EC, endometrioid carcinoma; CCC, clear cell 
carcinoma; UD, undifferentiated.
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Figure 2: Nutlin-3/RG7388 synergizes with cisplatin in wild-type TP53 ovarian cancer cells. A. Growth inhibition 
curves of three wild-type TP53 cell lines exposed to Nutlin-3 and CDDP alone, and in combination at constant 1:1 ratios of 
0.25X, 0.5X, 1X, 2X and 4X their respective GI
50
 concentration for 72 hours. B. Growth inhibition curves of three wild-type TP53 
cell lines exposed to RG7388 and CDDP alone, and in combination at constant 1:1 ratios of 0.25X, 0.5X, 1X, 2X and 4X their 
respective GI
50
 concentrations for 72 hours. C. The CI values for Nutlin-3/RG7388 in combination with cisplatin at ED
50
 and the 
average of CI values at effect levels ED
50
, ED
75
 and ED
90
 in three wild-type TP53 ovarian cancer cell lines. Data are shown as the 
average of at least 3 independent experiments and error bars represent SEM. Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; CI, 
Combination Index.
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dependent increase in the proportion of cells in G2/M 
phase and the proportion of SubG1 events compared 
to cisplatin on its own, particularly for A2780 cells 
(Figure 4A & 4B, Supplementary Figure S1A & S1B and 
Supplementary Figure S2A & S2B).
RG7388 alone after 24 hours treatment led to a 
higher increase in the proportion of cells in the G0/G1 
phase of the cell cycle across all cell lines compared to 
Nutlin-3 at the same GI
50
 doses (Figure 5A). RG7388 
induced SubG1 events in all cases in a concentration and 
Table 2: Growth inhibition CI values for RG7388/Nutlin-3 in combination with cisplatin for the wild-type TP53 
ovarian cancer cell lines 
Cell Line Combination CI CI ED50 CI ED75 CI ED90 CI Ave 
ED50-90XGI50
0.25 0.5 1 2 4
A2780
Nut-3+CDDP 0.5 0.4 0.4 0.6 1.0 0.3 0.5 0.8 0.5
RG+CDDP 1.2 0.5 0.5 0.5 0.9 0.7 0.7 0.6 0.7
IGROV-1
Nut-3+CDDP 0.8 0.7 1.0 1.6 2.2 0.8 1.4 2.5 1.5
RG+CDDP 0.8 0.8 0.7 1.1 1.9 0.8 1.5 5.1 2.4
OAW42
Nut-3+CDDP 1.0 1.1 1.3 1.7 1.5 1.1 1.4 1.9 1.5
RG+CDDP 1.3 1.2 1.5 2.1 3.1 1.1 3.5 5.6 3.4
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI
50
 concentrations. CI 
values were calculated for each constant ratio combination and at effect levels ED
50
, ED
75
 and ED
90
 from the average of at 
least three independent experiments. CI Ave ED
50-90
 represents the average of CI values at effect levels of ED
50
, ED
75
 and 
ED
90
. CI range: < 0.1 very strong synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 
0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 
antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism. Synergistic combinations are highlighted in bold font. 
Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; CI, Combination Index.
Table 3: DRI values for growth inhibition by RG7388/Nutlin-3 in combination with cisplatin for the wild-type 
ovarian cancer cell lines 
Cell Line Combination Component DRI
XGI50
0.25 0.5 1 2 4
A2780
Nut-3+CDDP
Nut-3 2.6 5.7 5.5 4.3 2.6
CDDP 4.3 6.9 6.4 5.2 3.2
RG+CDDP
RG7388 1.2 3.3 4.3 5.0 3.2
CDDP 3.3 4.5 3.7 3.0 1.7
IGROV-1
Nut-3+CDDP
Nut-3 2.3 3.2 2.5 1.6 1.2
CDDP 2.9 2.8 1.8 1.1 0.7
RG+CDDP
RG7388 1.8 2.5 5.5 6.2 4.5
CDDP 3.6 2.4 1.8 1.1 0.6
OAW42
Nut-3+CDDP
Nut-3 1.5 1.6 1.4 1.1 1.5
CDDP 3.6 2.9 2.0 1.4 1.3
RG+CDDP
RG7388 2.2 2.1 1.6 1.1 0.7
CDDP 4.5 3.2 2.0 1.2 0.7
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI
50
 concentrations. DRI 
values were calculated for each constant ratio combination from the average of at least three independent experiments. Favorable 
DRI values are highlighted in bold font. Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; DRI, Dose Reduction Index.
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time-dependent manner (Figure 5B, Supplementary Figure 
S3B and Supplementary Figure S4B). The IGROV-1 cell 
line showed a higher basal level of sub-G1 events on 
FACS analysis compared to the other cell lines, which 
was further increased by MDM2 inhibitor or cisplatin 
treatment.
In terms of the proportional distribution of cells 
in G0/G1 or G2/M, the effect of RG7388 combination 
with cisplatin was time dependent. Combined treatment 
for 24 hours led to proportionally more cells in the G0/
G1 cell cycle phase compared to the effect of cisplatin 
on its own and a higher proportion of cells in the G2/M 
phase compared to the effect of RG7388 alone across all 
3 cell lines (Figure 5A). After 48 and 72 hours treatment, 
the combination of RG7388 with cisplatin led to a greater 
proportional increase in G2/M phase compared to either 
agent alone for A2780 and IGROV-1, whereas for OAW42 
there was a reduction in the proportion of cells in G2/M 
phase (Supplementary Figure S3A and Supplementary 
Figure S4A).
The induction of apoptosis was also evaluated by 
caspase 3/7 enzymatic assay, which is a sensitive and 
specific indicator of apoptosis [17]. Wild-type TP53 
ovarian cancer cell lines were treated for 24 hours 
with 1x and 2x their respective Nutlin-3/RG7388 GI
50
 
concentrations as a single agent and in combination 
with cisplatin (Figure 4C & 5C). In general across the 
cell lines there was a positive correlation between the 
caspase 3/7 activity and accumulation of SubG1 events. 
With IGROV-1, a concentration-dependent increase in 
caspase 3/7 activity in response to Nutlin-3/RG7388 
compared to DMSO control was observed. Furthermore, 
Figure 3: Combination of Nutlin-3/RG7388 with cisplatin increased stabilization of p53 and upregulation of its 
downstream targets, MDM2 and p21WAF1 compared to cisplatin on its own. Total levels of p53, p21WAF1, MDM2 (4 hours) and 
BAX (8 hours) after the commencement of treatment with Nutlin-3 and RG7388 alone, and in combination with cisplatin at constant 1:1 
ratios of 1X and 2X their respective GI
50
 concentration analyzed by western blot in three wild-type TP53 ovarian cancer cell lines. Nutlin-3 
and RG7388 led to little change in BAX compared to DMSO control and combination of Nutlin-3 with cisplatin at 1X GI
50
 showed only a 
slight increase in the expression of BAX in A2780 and IGROV-1 cell lines compared to cisplatin on its own.
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the combination of Nutlin-3/RG7388 with cisplatin led to 
more caspase 3/7 activity in IGROV-1 compared to either 
agent alone. For A2780 there was no significant increase 
in the caspase 3/7 activity in response to Nutlin-3/RG7388 
alone. Also no significant increase was observed for the 
combination of Nutlin-3/RG7388 with cisplatin compared 
with the effect of cisplatin alone in the A2780 cells. 
Combination treatments led to a decrease in the caspase 
3/7 activity in the OAW42 cells indicating a protective 
effect of Nutlin-3/RG7388 against cisplatin in this cell line 
Figure 4: Combination of Nutlin-3 with cisplatin affects the cell cycle distribution and apoptotic endpoints. Wild-
type TP53 ovarian cancer cells were treated for 24 hours with Nutlin-3 or cisplatin alone and at constant 1:1 combination ratios of 1X 
and 2X ( 1/2 X & 1X for OAW42) their respective GI
50
 concentrations. A. Combination of Nutlin-3 with cisplatin led to an increased 
proportion of cells in G2/M phase compared to either agent alone in A2780 and IGROV-1 cell lines, B. FACS analysis for Sub-G1 
events and C. Caspase 3/7 activity as an indicator of apoptosis. Caspase 3/7 activity is represented as fold change relative to DMSO 
solvent control. Nut-3, Nutlin-3; CDDP, cisplatin; *, p ˂ 0.05; **, P < 0.01. Data are shown as the average of at least 3 independent 
experiments and error bars represent SEM. Statistically significant results were only shown in comparison with cisplatin on its own.
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(Figure 4C and Figure 5C). Taken together, these results 
demonstrated that the effect of Nutlin-3/RG7388 as a 
single agent and in combination with cisplatin on the cell 
cycle distribution, Sub-G1 events and caspase 3/7 activity 
is cell type, compound and time dependent.
Nutlin-3/RG7388 alone results in clonogenic cell 
death in a p53-dependent manner
Clonogenic survival assays were performed for 
the panel of six ovarian cancer cell lines. Exponentially 
Figure 5: Combination of RG7388 with cisplatin affects the cell cycle distribution and apoptotic endpoints. Wild-
type TP53 ovarian cancer cells were treated for 24 hours with RG7388 or cisplatin alone and at constant 1:1 combination ratios of 1X 
and 2X (1/2 X & 1X for OAW42) their respective GI
50
 concentrations. A. Combination of RG7388 with cisplatin led to an increased 
proportion of cells in G0/G1 phase compared to cisplatin on its own, B. FACS analysis for Sub-G1 events and C. Caspase 3/7 activity 
as an indicator of apoptosis. Caspase 3/7 activity is represented as fold change relative to DMSO solvent control. RG, RG7388; CDDP, 
cisplatin; *, p ˂ 0.05; **, P < 0.01. Data are shown as the average of at least 3 independent experiments and error bars represent SEM. 
Statistically significant results were only shown in comparison with cisplatin on its own.
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proliferating cell cultures were counted and seeded at 
appropriate densities for colony formation and treated with 
different concentrations of Nutlin-3/RG7388. The results 
showed TP53 mutant cell lines were significantly more 
resistant to Nutlin-3/ RG7388, but also demonstrated a 
wide range of responses for the wild-type TP53 cell lines 
(Figure 6A & Table 4). Nutlin-3 markedly decreased the 
clonogenic survival of A2780 cells (LC
50
= 1.65 ± 0.7 
(SEM) µM); however, IGROV-1 (LC
50
= 11 ± 2.1(SEM) 
µM) and OAW42 (LC
50
= 6.25 ± 0.50 (SEM) µM) were 
substantially less sensitive to Nutlin-3 (Figure 6A).
RG7388 was much more potent than Nutlin-3, 
and decreased the clonogenic survival of all the wild-
type TP53 ovarian cancer cell lines. Consistent with the 
mechanism of action for MDM2 antagonists, RG7388 
had little or no effect on mutant TP53 cell lines in the 
0-2µM dose range (Figure 6B). Interestingly, although 
all three cell lines were sensitive to RG7388, the relative 
sensitivity of the wild-type TP53 cell lines to Nutlin-3 and 
RG7388 was very different. The clonogenic cell survival 
response to RG7388 for A2780 and OAW42 was similar, 
whereas for Nutlin-3 their relative responses were quite 
different, with only A2780 showing sensitivity to Nutlin-3. 
Overall, the clonogenic cell survival assays showed 
not only that mutant TP53 genomic status was a major 
determinant of resistance to Nutlin-3 and RG7388, but 
also that the relative response of the wild-type TP53 cell 
lines differed for the two MDM2 inhibitors in a way that 
was not explicable simply by the relative potency of the 
compounds in cell-free MDM2-p53 binding assays.
Nutlin-3/RG7388 and cisplatin are synergistic 
for clonogenic cell killing of wild-type TP53 
ovarian cancer cell lines
The reduction in clonogenic survival in response 
to 48 hours exposure to Nutlin-3, RG7388 and cisplatin, 
both as single agents and in combination at five equipotent 
concentrations between 0.25× and 4× their respective 
LC
50
 concentrations was determined for the three wild-
type TP53 cell lines and evaluated by median effect 
analysis. Due to the high LC
50
 for IGROV-1 and OAW42 
in response to Nutlin-3, 3 equipotent concentrations 
between 0.25× and 1x their respective LC
50
 concentrations 
Figure 6: Clonogenic survival for the panel of ovarian cancer cell lines. Treatment with A. Nutlin-3 and B. RG7388. Clonogenic 
cell survival LC
50
 values were dependent on the TP53 genomic status. TP53 mutant cell lines are indicated in bold font. Nut-3, Nutlin-3; 
RG, RG7388; CDDP, cisplatin. Data are shown as the average of at least 3 independent experiments and error bars represent SEM.
Table 4: LC50 concentrations for cisplatin, Nutlin-3 and RG7388 for the panel of ovarian cancer cell lines of varying 
TP53 status 
Cell line TP53 status Cisplatin (µM) Nutlin-3 (µM) RG7388 (µM) 
A2780 Wild-type 0.42 ± 0.0003 1.65 ± 0.71 0.14 ± 0.03
IGROV-1 Wild-type 0.82 ± 0.06 11 ± 2.08 0.67 ± 0.15
OAW42 Wild-type 0.28 ± 0.01 6.25 ± 0.50 0.15 ± 0.04
CP70 Mutant 3.39 ± 0.05 ˃ 32 >2
MDAH-2774 Mutant 0.67 ± 0.08 ˃ 32 >2
SKOV-3 Mutant 1.87 ± 0.42 ˃ 32 >2
Data represent the mean of at least 3 independent experiments ± SEM.
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were used to assess the combination effect of Nutlin-3 
with cisplatin. The effect of combined treatment was cell 
type and compound dependent (Figure 7A & 7B). The 
combination of Nutlin-3 with cisplatin led to a further 
decrease in colony formation compared to treatment 
with either agent alone for all three cell lines and was 
particularly marked for IGROV1.
Although the combination of Nutlin-3 with 
cisplatin significantly decreased the clonogenic survival 
of IGROV-1 and A2780 compared to either agent alone, 
the combined treatment of RG7388 with cisplatin at 
the same LC
50
 ratios only moderately reduced colony 
formation (Figure 7A & 7B). For the OAW42 cell line, the 
combination treatment of Nutlin-3 with cisplatin reduced 
the ability of the OAW42 cell line to form colonies to a 
greater extent than either agent on its own. In contrast, 
there was no significant reduction in the clonogenic cell 
survival of OAW42 following combination treatment 
with RG7388 and cisplatin compared to either agent alone 
(Figure 7A & 7B).
The data were analyzed using median-effect analysis 
and CI values calculated to evaluate whether the observed 
differences in clonogenic cell survival were synergistic, 
additive or antagonistic. CI values for each constant ratio 
combination at estimated effect levels of ED
50
, ED
75
 and 
ED
90
 were individually computed, and the average of CI 
values was also determined. Across all three wild-type 
TP53 cell lines, the effect of combination treatment of 
Nutlin-3 with cisplatin ranged from additive to strongly 
synergistic (Table 5 and Figure 7C). In addition, for 
combination treatments, both Nutlin-3 and cisplatin had 
a favorable DRI ranging from 1.3-fold to 10.9-fold dose 
reduction (Table 6).
For A2780 and IGROV-1 cell lines a synergistic 
effect was observed for combination treatment with 
Nutlin-3 and cisplatin, whereas for RG7388 and cisplatin 
combinations the effect was additive to antagonistic. 
For the OAW42 cell line the combination of RG7388 
and cisplatin was antagonistic, suggesting RG7388 
had a protective effect against cisplatin (Table 5 and 
Figure 7C). Although the combined effect of RG7388 
with cisplatin ranged from additive to antagonistic, there 
was nevertheless a favorable DRI for the same level of 
clonogenic cell killing when treatments are combined for 
all RG7388 concentrations and most concentrations of 
cisplatin (Table 6).
Nutlin-3/RG7388 induces expression of cell 
cycle arrest/ apoptosis-related genes and those 
involved in response to DNA repair
To investigate the mechanistic basis for the observed 
combination effects, the effect of MDM2 inhibitor 
treatment on mRNA expression of candidate genes with 
potential for influencing the response to cisplatin was 
analyzed by quantitative real time polymerase chain 
reaction (qRT-PCR). Changes in the expression of cell 
cycle/apoptosis-related genes as well as those involved 
in nucleotide excision repair (NER) and mismatch repair 
(MMR) for the three wild-type TP53 cell lines in response 
to Nutlin-3 and RG7388 are shown in Figure 8 & 9. The 
cells were treated with 5 (µM) Nutlin-3 and 0.5 (µM) 
RG7388, and the total RNA was extracted 6 hours after 
the commencement of treatment.
Overall, the fold changes in expression in response 
to MDM2 inhibitors were less in A2780 cells than 
IGROV-1 and OAW42 (Figure 8 & 9). In the case of the 
genes involved in cell cycle arrest and growth inhibition, 
Nutlin-3 and RG7388 treatment significantly induced 
CDKN1A, SESN1 and GADD45A gene expression in 
all three cell lines, with CDKN1A consistently showing 
the highest level of induction (p<0.05) (Figure 8 & 9). 
Both treatments showed a significant increase in the 
expression of the pro-apoptotic TNFRSF10B and BBC3 
(PUMA) genes in all three cell lines, with increases of 
BBC3 mRNA being highest in the IGROV-1 cell line 
(p<0.05) (Figure 8). The Nutlin-3/RG7388 treatment also 
increased expression of the pro-apoptotic gene TP53INP1 
in A2780 and OAW42 cells; however, there was no 
significant induction in IGROV-1. No significant increase 
was observed for the pro-apoptotic gene BAX in any of 
the cell lines. Although Nutlin-3/RG7388 treatment led to 
significantly increased expression of AEN in IGROV-1, 
the induction of AEN was not statistically significant 
for A2780 and OAW42 (Figure 8). Furthermore, both 
Nutlin-3 and RG7388 treatments significantly increased 
the expression of the anti-apoptotic MDM2 gene across 
all three cell lines. The treatments led to a statistically 
significant decrease in the expression of BCL-2 although 
the changes were small and unlikely to be biologically 
significant. Also no significant changes were observed 
in the expression levels of the anti-apoptotic BIRC5 and 
MCL-1 genes (Supplementary Figure S5).
To study the effect of Nutlin-3 and RG7388 on 
the expression of genes implicated in the response to 
DNA repair induced by cisplatin, the expression of 
TP53BP1, DDB2, ERCC1, XPC, MLH1, MSH2, RAD51 
and RRM2B genes in response to Nutlin-3 and RG7388 
was investigated. A significant increase was measured 
in the expression of DDB2 in response to Nutlin-3 and 
XPC in response to both Nutlin-3 and RG7388 for 
A2780 cells (p<0.05). In the case of IGROV-1, XPC 
and MSH2 gene expression levels were significantly 
induced and reduced respectively in response to both 
Nutlin-3 and RG7388 (p<0.05). For OAW42 cells there 
was a significant increase in the expression of DDB2 
and XPC genes and a significant decrease in the MLH1 
and MSH2 expression levels in response to Nutlin-3 and 
RG7388 treatment (p<0.05). With Nutlin-3 treatment, 
the TP53BP1 gene expression decreased in all three cell 
lines, although statistically this trend was not significant 
(p>0.05).
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Figure 7: Nutlin-3/RG7388 has a synergistic or additive effect with cisplatin in clonogenic survival assays in wild-type 
TP53 ovarian cancer cells. A. Clonogenic survival for three wild-type TP53 cell lines exposed to Nutlin-3 and CDDP alone, and in 
combination at constant 1:1 ratios of 0.25X, 0.5X, 1X, 2X and 4X (A2780) and 0.25X, 0.5X, 1X (IGROV-1 & OAW42) their respective 
LC
50
 concentration for 48 hours. B. Clonogenic survival for three wild-type TP53 cell lines exposed to RG7388 and CDDP alone, and in 
combination at constant 1:1 ratios of 0.25X, 0.5X, 1X, 2X and 4X their respective LC
50
 concentration for 48 hours. C. The CI values for 
Nutlin-3/RG7388 in combination with cisplatin at ED
50
 and, the average of CI values at effect levels ED
50
, ED
75
 and ED
90
 in three wild-type 
TP53 ovarian cancer cell lines. Data are shown as the average of at least 3 independent experiments and error bars represent SEM. Nut-3, 
Nutlin-3; RG, RG7388; CDDP, cisplatin, CI, Combination Index.
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The mRNA profile found for CDKN1A and BAX 
genes was consistent with the western blot analysis for 
p21WAF1 and BAX proteins (Figure 1B, 1C and Figure 3). 
The increased CDKN1A and SESN1 gene expression 
is also in agreement with induced cell cycle arrest and 
growth inhibition across the three cell lines. Furthermore, 
induction of BBC3 and TNFRSF10B is in accordance with 
the induction of apoptosis, Sub-G1 events and caspase 3/7 
Table 5: Clonogenic survival CI values for RG7388/Nutlin-3 in combination with cisplatin for the wild-type TP53 
ovarian cancer cell lines 
Cell Line Combination CI CI ED50 CI ED75 CI ED90 CI Ave 
ED50-90XGI50
0.25 0.5 1 2 4
A2780
Nut-3+CDDP 1.9 0.4 0.4 0.6 0.6 0.7 0.6 0.6 0.7
RG+CDDP 1.2 1.0 1.0 1.0 0.9 1.0 1.0 0.9 1.0
IGROV-1
Nut-3+CDDP 0.4 0.5 0.7 ND ND 0.2 0.4 0.9 0.5
RG+CDDP 0.8 1.0 1.4 1.9 1.9 0.9 1.1 1.4 1.1
OAW42
Nut-3+CDDP 1.8 1.0 1.0 ND ND 1.1 1.0 1.0 1.0
RG+CDDP 1.2 1.9 1.7 1.7 1.7 1.8 1.7 1.7 1.7
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI
50
 concentrations. CI 
values were calculated for each constant ratio combination and at effect levels ED
50
, ED
75
 and ED
90
 from the average of at 
least three independent experiments. CI Ave ED
50-90
 represents the average of CI values at effect levels of ED
50
, ED
75
 and 
ED
90
. CI range: < 0.1 very strong synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 
0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 
antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism. Synergistic combinations are highlighted in bold font. 
Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; CI, Combination Index; ND; Not determined.
Table 6: DRI values for clonogenic cell killing by RG7388/Nutlin-3 in combination with cisplatin in wild-type TP53 
ovarian cancer cell lines
Cell Line Combination Component DRI
XGI50
0.25 0.5 1 2 4
A2780
Nut-3+CDDP
Nut-3 1.3 7.3 10.7 7.8 10.9
CDDP 2.1 4.0 3.4 2.2 2.0
RG+CDDP
RG7388 1.6 1.9 2.0 2.5 3.5
CDDP 3.2 2.6 2.1 1.8 1.7
IGROV-1
Nut-3+CDDP
Nut-3 6.4 5.4 4.1 ND ND
CDDP 5.1 3.7 2.2 ND ND
RG+CDDP
RG7388 4.3 4.3 4.3 4.5 11.0
CDDP 2.1 1.4 0.9 0.6 0.6
OAW42
Nut-3+CDDP
Nut-3 1.6 1.5 1.3 ND ND
CDDP 1.8 3.2 5.0 ND ND
RG+CDDP
RG7388 1.0 1.1 1.2 1.4 2.0
CDDP 2.1 1.7 1.4 1.1 0.9
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective LC
50
 concentrations. 
DRI values were calculated for each constant ratio combination from the average of at least three independent experiments. 
Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; DRI, Dose Reduction Index; ND; Not determined; Favorable DRI values 
are highlighted in bold font.
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activity, in A2780 and IGROV-1 (Figure 4B, Figure 4C, 
Figure 5B and 5C). However, in spite of significantly 
increased BBC3 and TNFRSF10B gene expression levels 
in OAW42, no induction of apoptosis was observed in this 
cell line (Figure 4B, Figure 4C, Figure 5B and 5C).
The increased sensitivity to MDM2 inhibitors and their 
synergy with cisplatin observed with the A2780 cells was not 
obviously attributable to any individual change in candidate 
gene expression. However, as can be seen in Figure 9, the 
balance of expression between the growth arrest genes and 
Figure 8: mRNA expression of genes relating to apoptosis, cell cycle arrest, nucleotide excision repair (NER) and DNA 
mismatch repair in response 5 µM Nutlin-3 or 0.5 µM RG7388 for 6 hours relative to DMSO solvent control. A. A2780, B. 
IGROV-1 and C. OAW42, *, p ˂  0.05; **, P < 0.01. Data are presented as mean ± standard error of mean (SEM) of three independent repeats.
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the autoregulatory negative feedback MDM2 gene on the 
one hand and the pro-apoptotic and DNA repair genes on the 
other hand, was clearly less with the A2780 cells.
DISCUSSION
Advanced ovarian cancer treatment usually involves 
a combination of debulking surgery and platinum based 
chemotherapy, alone or with the addition of paclitaxel. 
Although chemotherapy prolongs survival, most patients 
with advanced disease die from treatment resistant 
progressive disease [18]. Cancer therapy has recently 
been improving with the introduction of targeted therapies 
to achieve greater specificity and less cytotoxicity [19]. 
This study evaluates for the first time the effect of the 
MDM2-p53 binding antagonist RG7388, as a single agent 
in a panel of ovarian cancer cell lines of defined TP53 
genomic status. It also investigates the effect of RG7388 or 
Figure 9: Growth arrest, pro-apoptotic, anti-apoptotic and DNA repair-related gene expression changes induced by 
5 µM Nutlin-3 or 0.5 µM RG7388 for 6 hours relative to DMSO solvent control. Summary data are presented as a combination 
of three independent repeats for Nutlin-3 and three for RG7388.
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Nutlin-3 in combination with cisplatin in wild-type TP53 
ovarian cancer cell lines and explores the mechanistic 
basis for the growth inhibitory and cytotoxic responses.
Within the panel of ovarian cancer cell lines studied, 
wild-type TP53 cell lines were significantly more sensitive 
to Nutlin-3 and the more potent RG7388 compared to 
mutant TP53 cell lines. Consistent with their mechanism 
of action, Nutlin-3 and RG7388 treatment led to more 
p53 stabilization and induction of p21WAF1 and MDM2 in 
the wild-type TP53 ovarian cancer cell lines. There was 
no upregulation of p53 downstream target genes in TP53 
mutant ovarian cancer cell lines in response to Nutlin-3 
and RG7388 treatment [20]. Interestingly, despite the 
lack of downstream function, there was some evidence 
of mutant p53 stabilization in response to treatment with 
MDM2 inhibitors in the TP53 mutant CP70 and MLH1-
corrected CP70+ cell lines. This suggests some mutant 
forms of p53 still show evidence of degradation by MDM2 
which is prevented by the MDM2 inhibitors. These results 
are consistent with limited previous studies [10, 21] 
demonstrating that wild-type TP53 ovarian cancer cell 
lines are responsive to Nutlin-3 and extends observations 
to the second generation MDM2 inhibitor RG7388 
currently in early phase clinical trials.
Resistance to MDM2-p53 binding antagonists has 
been suggested to be acquired by prolonged exposure of 
cells to sub-lethal doses through de novo inactivating TP53 
mutations or selection of pre-existing subclones of TP53 
mutant cells that might be present as a result of cancer 
cell genomic instability and tumor heterogeneity [22, 23]. 
For this reason, it is suggested that MDM2-antagonists 
are likely be most effective in combination with standard 
existing chemotherapeutic agents or agents that target or 
limit the potential outgrowth of TP53 mutated cells. The 
major benefits of combination therapy are the potential 
for a synergistic therapeutic effect, dose and toxicity 
reduction, and delay or prevention of drug resistance 
[24, 25]. Platinum agents used to treat ovarian cancer 
have major adverse side effects including nephrotoxicity, 
ototoxicity, myelosuppression and gastrointestinal 
disorders [26]. This study set out with the aim of assessing 
the effect of single and combination treatment of Nutlin-3 
and RG7388 with cisplatin in a panel of ovarian cancer 
cell lines of known TP53 status. The effects observed 
were compound and cell type dependent. Overall, the 
combination effect of Nutlin-3 and RG7388 with cisplatin 
ranged from synergism in A2780 and moderate synergism 
to antagonism in IGROV-1 and OAW42 cell lines. 
A single limited previous study examined the combination 
of Nutlin-3a with cisplatin in A2780p, A2780cis and the 
OV90 cell lines. The results showed a synergistic effect 
in A2780p and A2780cis, consistent with our study [10].
Even in the absence of synergy, combined treatment 
can nevertheless be of potential clinical use, because in 
most cases a favorable dose reduction for each agent may 
still be achievable for a given level of effect compared 
with each agent alone (Tables 3 and 6). This is of 
particular potential benefit when the agents in question, 
in this case MDM2 inhibitors and cisplatin, have different 
dose limiting toxicities. [27].
The combination treatments increased stabilization 
of p53 and upregulation of p21WAF1 compared to either 
agent alone, particularly compared to cisplatin in A2780 
and IGROV-1. However, there was no significant 
increase in p53 stabilization and p21WAF1 upregulation 
in combined treatment of OAW42 cells compared to 
Nutlin-3 and RG7388 as single treatments. These results 
help to understand the observed differences in the effect of 
combined treatment on growth inhibition and clonogenic 
cell survival between these cell lines. These findings are 
in keeping with functional activation of p53 as a driver 
of the synergistic effects in combination treatment. For 
growth inhibition the increased upregulation of p21WAF1 is 
consistent with its role in cell cycle arrest [28].
Individually, Nutlin-3 and RG7388 induced cell 
cycle arrest in wild-type TP53 ovarian cancer cell lines 
in a time and dose-dependent manner. When cells were 
treated with the GI
50
 isoeffect doses of RG7388 or 
Nutlin-3, RG7388 had a greater effect on the cell cycle 
distribution, with increased accumulation of cells in G0/
G1. Combination treatment with Nutlin-3 or RG7388 and 
cisplatin led to greater G2/M and/or G0/G1 cell cycle 
phase accumulation, more SubG1 events and/or higher 
levels of caspase 3/7 activity compared to either agent 
alone in a cell type and time dependent manner. Overall, 
there was a positive correlation between the detection of 
SubG1 events on FACS analysis and caspase 3/7 activity, 
however cell cycle arrest is not always accompanied by 
the induction of apoptosis [29] as seen for OAW42 cells 
in this study. The apparent protective effect of Nutlin-3/
RG7388 against cisplatin in OAW42, indicated by the 
antagonistic effect of combination (Figure 2C and 7C), 
was reflected by fewer SubG1 events and Caspase 3/7 
activity compared to cisplatin on its own.
The clonogenic cell survival assays also showed 
TP53 mutant cell lines were much more resistant to 
Nutlin-3 and RG7388, but nevertheless also demonstrated 
a range of different relative single agent responses for 
the wild-type TP53 cell lines (Figure 6 and Table 4). 
A possible explanation for this range of responses between 
the wild-type TP53 cell lines might be due to differences 
in drug uptake [30] or deficiencies or variation in the 
expression of p53 target genes involved in apoptosis 
and other mechanisms of cell death, including the pro-
apoptotic proteins BAX and PUMA and anti-apoptotic 
proteins BCL-2 and MCL-1 [31, 32].
Combined treatment with Nutlin-3 and cisplatin 
significantly decreased the clonogenic survival of wild-
type TP53 ovarian cancer cells compared with either agent 
alone, and the combination effect ranged from additive 
to strong synergy. Nutlin-3 may sensitize wild-type 
TP53 ovarian cancer cell lines to cisplatin via multiple 
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factors including increased p53-dependent apoptosis 
[33, 34]. Surprisingly, the combination of RG7388 with 
cisplatin showed no evidence of synergy for reduction 
of colony forming ability. The clonogenic assay results 
for combination of RG7388 with cisplatin ranged from 
antagonism for OAW42, indicating a protective effect 
of RG7388 against cisplatin, to additive for A2780 
and IGROV-1. The difference between the results for 
combination of cisplatin with Nutlin-3 compared to 
the combination with RG7388 may in part be due to 
different p53-dependent off-target effects of these MDM2 
inhibitors. A contributory factor may be differences 
in G1 cell cycle arrest with MDM2 inhibitors, since an 
increased G1 cell cycle arrest may protect against agents 
such as cisplatin which are preferentially cytotoxic against 
S-phase cells [35].
Across the 3 cell lines, Nutlin-3/RG7388 
increased CDKN1A and SESN1 expression consistent 
with their essential role in cell cycle arrest and growth 
inhibition [36, 37]. Both Nutlin-3 and RG7388 treatment 
significantly induced the expression of the pro-apoptotic 
TNFRSF10B and BBC3 genes in all 3 cell lines. The 
TNFRSF10B receptor and its ligand, TRAIL, have been 
reported to preferentially induce apoptosis in transformed 
and tumor cells even though it is expressed at a significant 
level and may be induced in normal tissues [38, 39]. 
This may contribute to the generally greater toxicity of 
MDM2 inhibitors for cancer cells compared to normal 
cells, although some haematopoetic cell lineages also 
appear to be sensitive, as evidenced by the dose limiting 
thrombocytopenia seen in the early phase clinical trials of 
MDM2 inhibitors [40]. There was a positive concordance 
between the expression of these pro-apoptotic genes and 
the apoptotic endpoints shown by Sub-G1 signals on 
FACS analysis and caspase 3/7 activity in A2780 and 
IGROV-1 cell lines. However, this relationship did not 
extend to the OAW42 cell line, which despite increased 
TNFRSF10B, TP53INP1 and the highest pro-apoptotic 
BBC3 expression was not in keeping with low caspase 
3/7 activity and SubG1 FACS signals. Failure to undergo 
apoptosis in OAW42 cells in response to C1311, a new 
class of imidazoacridinones, has also been reported, 
consistent with our observation [41].
A possible explanation for the lack of evidence of 
apoptosis in OAW42 might be high expression of anti-
apoptotic proteins such as BCL-2, BCL-X and MCL-1, 
or deficiency in downstream factors involved in the 
apoptosis cascade [27, 28]. Although BAX is required 
for PUMA-induced apoptosis, there was no significant 
increase in BAX expression, either at the mRNA or 
protein level in response to Nutlin-3/RG7388 treatment 
in any of the cell lines.
Significantly increased expression of several p53-
regulated genes involved in the repair of DNA lesions 
induced by cisplatin, including DDB2, XPC and RRM2B, 
lead us to reject the hypothesis that reduced capacity 
for repair of cisplatin induced DNA damage leads to a 
synergistic effect in combined treatment with Nutlin-3/
RG7388 and cisplatin. Although there was some evidence 
of a reduced expression of the DNA mismatch repair 
genes, MLH1 and MSH2, the changes were very small and 
unlikely to be biologically significant.
In conclusion, the present study demonstrates that 
RG7388 has activity as a single agent against wild-type 
TP53 ovarian cancer cells, leading to cell cycle arrest 
and/or apoptosis. In addition, combination treatment with 
MDM2 inhibitors and cisplatin has synergistic and/or 
dose reduction potential dependent on cell genotype and 
compound and merits further investigation. Our study 
clearly indicates that the presence of wild-type TP53 
remains the main predictive biomarker of response to 
MDM2 inhibitors. However, additional determinants of 
response involve the balance of activity between growth 
inhibitory/pro-survival and pro-apoptotic genes and our 
results indicate that this dominates the small changes in 
the expression of DNA repair genes as an explanation 
for the synergy observed for treatment with cisplatin and 
MDM2 inhibitors.
MATERIALS AND METHODS
Chemicals and antibodies
Nutlin-3, a 1:1 mixture of the active enantiomer 
Nutlin-3a and the inactive enantiomer Nutlin-3b, was 
purchased from NewChem (Newcastle, UK) and RG7388 
was kindly provided by Professor Herbie Newell and made 
available by the Newcastle Anticancer Drug Development 
Initiative. Both were dissolved in dimethyl sulfoxide 
(DMSO). Cisplatin (Merck Millipore, Watford, UK) was 
dissolved in distilled water.
Cell lines
The ovarian cancer cell lines used in this study, their 
TP53 status and histological subtype are listed in Table 1. 
All cell lines were sourced from the NICR authenticated 
cell bank and regularly tested for Mycoplasma. A2780, 
IGROV-1, OAW42 and CP70 were cultured in RPMI-
1640 supplemented with 10% (v/v) FBS and 5% (v/v) 
penicillin/streptomycin. The CP70 cell line harbors a 
heterozygous TP53 mutation (c.514 G->T, p.Val172Phe) 
[42].The MLH1-corrected CP70+ cell line was grown 
in RPMI-1640 supplemented with 10% (v/v) FBS and 
Hygromycin B (200 µg/ml: Life Technologies, Inc.) [42]. 
This cell line has the heterozygous TP53 mutation (c.514 
G->T, p.Val172Phe). SKOV-3 and MDAH-2774 cell lines 
were cultured in DMEM supplemented with 10% and 
5% (v/v) FBS and penicillin/streptomycin respectively. 
As information on the TP53 status of SKOV-3 in the 
literature was contradictory, sequencing was performed 
and a frame shift deletion (c.265delC, p.Pro89fsX33) was 
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confirmed (Supplementary Figure S5). The MDAH-2774 
harbors a TP53 mutation located in exon 8 (c.818G->A, 
p.Arg273His) [43].
Growth inhibition assays and median-effect 
analysis
The GI
50
 values, the required concentrations of 
each compound leading to 50% growth inhibition, were 
determined by Sulforhodamine B (SRB) growth inhibition 
assays for drug exposure over 72 hours and the absorbance 
of the re-dissolved SRB protein stain was measured at 570 
nm using a 96-well plate spectrophotometer (Spectramax 
250 Molecular Devices) [44]. Growth curves were 
constructed using GraphPad Prism statistical analysis 
software version 5.04. For combination treatment of 
Nutlin-3 or RG7388 with cisplatin, the wild-type TP53 
cell lines were treated for 72 hours with each agent 
alone and in combination simultaneously at constant 
1:1 ratios of 0.25x, 0.5x, 1x, 2x, and 4x their respective 
GI
50
 concentrations. Median-effect analysis was used to 
calculate Combination Index (CI) and Dose Reduction 
Index (DRI) values [27] using CalcuSyn software v2 
(Biosoft, Cambridge, UK).
Western blotting
Lysis buffer (12.5 ml Tris HCL, 2g SDS, 10 ml 
Glycerol, 67.5 ml Distilled Water) was used to harvest 
whole-cell lysates, followed by sonication. The concentration 
of protein in the cell lysates was estimated by using a 
bicinchoninic acid (BCA) assay. Novex® 4-20% Tris-
Glycine 12-well polyacrylamide gradient gels (Invitrogen, 
UK) were used to separate proteins. The separated proteins 
were transferred by perpendicular electrophoresis to 
a nitrocellulose HybondTM C membrane (Amersham, 
Buckinghamshire, UK). Monoclonal Mouse Anti-Human 
primary antibodies Actin 1:1000 (#: A4700, Sigma-Aldrich), 
MDM2 1:300 (#: OP46-100UG, Merck Millipore), p21WAF1 
1:100 (#: OP64, Calbiochem), p53 1:500 (#: NCL-L-p53-
DO7, Leica Microsystems Ltd.) and Polyclonal Rabbit 
Anti-Human primary antibody BAX 1:1000 (#: 2772S, 
Cell Signalling) were used. Secondary goat anti-mouse/
rabbit HRP-conjugated antibodies (#: P0447/P0448, Dako) 
were used at 1:1000. All antibodies were diluted in 5% 
milk/1XTBS-Tween (w/v). Enhanced chemiluminescence 
(GE Life Sciences) and X-ray film (Fujifilm) were used to 
visualize the proteins.
Flow cytometry
Cells were treated with Nutlin-3, RG7388 and 
cisplatin alone and with combinations of Nutlin-3 or 
RG7388 with cisplatin simultaneously at constant 1:1 
ratios of 1x and 2x (A2780 and IGROV-1) or 0.5x and 
1x (OAW42) their respective GI
50
 concentrations for 24, 
48 and 72 hours. Cells harvested by trypsinisation were 
washed with PBS and resuspended in 500 μL PBS with 
1mg/mL sodium citrate (Sigma, St Louis, MO), 100 
µg/mL propidium iodide (Sigma), 200 µg/mL RNAse 
A (Sigma) and 0.3% Triton-X (Sigma). Samples were 
analyzed on a FACSCaliburTM flow cytometer using 
CellQuest Pro software (Becton Dickinson, Oxford, UK). 
Cell cycle distribution was determined using Cyflogic 
(CyFlo Ltd, Turku, Finland).
Clonogenic cell survival assay
Based on the drug concentration and sensitivity of 
cell lines, 100 to 100,000 cells were seeded into triplicate 
six-well plates. Cells were treated with Nutlin-3, RG7388 
and cisplatin alone and in combination at constant 1:1 
ratios of 0.25x, 0.5x, 1x, 2x and 4x or 0.25x, 0.5x and 1x 
their respective LC
50
 concentrations, depending on the cell 
line and its single agent LC
50
 values, for 48 hours. Then, 
the medium including drug was removed and drug-free 
medium was added. The cells were incubated for 2 to 3 
weeks to form colonies for counting (a colony was defined 
as a focus of ≥50 cells). After that, the plates were washed 
with PBS, fixed with methanol/acetic acid (3:1) and 
stained with 0.5% (w/v) crystal violet. Plates were again 
washed and then left at room temperature to dry. The LC
50
 
values were calculated using GraphPad Prism statistical 
analysis software version 5.04. DRI and CI values were 
calculated by median-effect analysis [27] using CalcuSyn 
software v2 (Biosoft, Cambridge, UK).
Caspase 3/7 activity assay
Caspase 3/7 activity was measured using a Caspase- 
Glo 3/7 assay following the manufacturer’s instructions 
(Promega, Southampton, UK).
qRT-PCR
Total RNA was extracted using an RNeasy Mini Kit 
(Qiagen, Germany). RNA purity and concentration were 
estimated with an ND-1000 spectrophotometer (NanoDrop 
Technologies, Thermo Scientific, UK). Total messenger 
RNA was converted to cDNA using the Promega Reverse 
Transcription System (A3500, Promega) as described by 
the manufacturer. Validated primers used (Sigma-Aldrich 
UK) are listed in Supplemental Table 1 & 2. qRT-PCR was 
carried out using SYBR® green RT-PCR master mix (Life 
technologies) according to the manufacturer’s guidelines. 
PCR reactions with 50ng/μl of the cDNA samples per 10μl 
final reaction volume, were performed using standard cycling 
parameters (Stage 1: 50˚C for 2min, Stage 2: 95˚C for 10min 
then 40 cycles of 95˚C for 15 Sec and 60˚C for 1 min) on 
an ABI 7900HT sequence detection system. GAPDH was 
used as endogenous control and the DMSO solvent control 
sample used as the calibrator for each independent repeat. 
Data analysis using the ΔΔCt Method was carried out using 
SDS 2.2 software (Applied Biosystems).
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Statistical analysis
All statistical tests presented were carried out using 
GraphPad Prism version 5.04 software. A p-value of <0.05 
was considered to be statistically significant based on at 
least n=3 experimental repeats.
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